FDA Accepts NDA Resubmission for DEXTENZA Biopharma, FDA, FDA/Regulatory, New Drug Application (NDA), Ocular Pain, Ophthalmics, PDUFA Ocular Therapeutix’s NDA resubmission for DEXTENZA 0.4 mg for ocular pain occurring after ophthalmic surgery was accepted as a filing for review by FDA. Read more February 22, 2017/by Business Wire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Business Wire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Business Wire2017-02-22 08:00:352017-02-22 14:40:52FDA Accepts NDA Resubmission for DEXTENZA
